Management issues in paroxysmal nocturnal hemoglobinuria

Gabrielle Meyers, Charles J. Parker

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) arises in the setting of bone marrow injury. Thus, management decisions must take into account whether symptoms are a consequence of the underlying marrow failure or of the expansion of the clone of the PIG-A mutant hematopoietic cells. The primary clinical manifestations of PNH are intravascular hemolysis and thrombophilia. Currently available options for treatment of the hemolysis of PNH are unsatisfactory, but the recent development of specific inhibitors of complement for use in treating human disease should make possible effective management of this pathology. The fundamental basis of the thrombophilia of PNH has not been elucidated. Currently, empiric anticoagulant therapy is the foundation for treating the thromboembolic complications of PNH. The role of warfarin prophylaxis, however, remains an area of active debate. Pregnancy in a patient with PNH presents special concerns about fetal/maternal well-being because of the high potential for thromboembolic complications. Bone marrow transplantation can be considered curative, but the decision to recommend this treatment must take into account factors related both to PNH and to comorbid conditions. Refining the technology for both gene therapy (by transducing stem cells with a functional PIG-A gene) and autotransplantation (by using stem cells selected for the expression of glycosyl phosphatidylinositol-anchored proteins) remain challenges for the future.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalInternational Journal of Hematology
Volume77
Issue number2
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

Paroxysmal Hemoglobinuria
Thrombophilia
Complement Inactivating Agents
Hemolysis
Stem Cells
Bone Marrow
Glycosylphosphatidylinositols
Autologous Transplantation
Warfarin
Bone Marrow Transplantation
Genetic Therapy
Anticoagulants
Therapeutics
Clone Cells
Mothers
Pathology
Technology
Pregnancy
Wounds and Injuries

Keywords

  • Complement
  • Hemolysis
  • PNH
  • Therapy
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Management issues in paroxysmal nocturnal hemoglobinuria. / Meyers, Gabrielle; Parker, Charles J.

In: International Journal of Hematology, Vol. 77, No. 2, 02.2003, p. 125-132.

Research output: Contribution to journalArticle

@article{98be3cfc6c1b47eb9661a44e755fe62a,
title = "Management issues in paroxysmal nocturnal hemoglobinuria",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) arises in the setting of bone marrow injury. Thus, management decisions must take into account whether symptoms are a consequence of the underlying marrow failure or of the expansion of the clone of the PIG-A mutant hematopoietic cells. The primary clinical manifestations of PNH are intravascular hemolysis and thrombophilia. Currently available options for treatment of the hemolysis of PNH are unsatisfactory, but the recent development of specific inhibitors of complement for use in treating human disease should make possible effective management of this pathology. The fundamental basis of the thrombophilia of PNH has not been elucidated. Currently, empiric anticoagulant therapy is the foundation for treating the thromboembolic complications of PNH. The role of warfarin prophylaxis, however, remains an area of active debate. Pregnancy in a patient with PNH presents special concerns about fetal/maternal well-being because of the high potential for thromboembolic complications. Bone marrow transplantation can be considered curative, but the decision to recommend this treatment must take into account factors related both to PNH and to comorbid conditions. Refining the technology for both gene therapy (by transducing stem cells with a functional PIG-A gene) and autotransplantation (by using stem cells selected for the expression of glycosyl phosphatidylinositol-anchored proteins) remain challenges for the future.",
keywords = "Complement, Hemolysis, PNH, Therapy, Thrombosis",
author = "Gabrielle Meyers and Parker, {Charles J.}",
year = "2003",
month = "2",
language = "English (US)",
volume = "77",
pages = "125--132",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Management issues in paroxysmal nocturnal hemoglobinuria

AU - Meyers, Gabrielle

AU - Parker, Charles J.

PY - 2003/2

Y1 - 2003/2

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) arises in the setting of bone marrow injury. Thus, management decisions must take into account whether symptoms are a consequence of the underlying marrow failure or of the expansion of the clone of the PIG-A mutant hematopoietic cells. The primary clinical manifestations of PNH are intravascular hemolysis and thrombophilia. Currently available options for treatment of the hemolysis of PNH are unsatisfactory, but the recent development of specific inhibitors of complement for use in treating human disease should make possible effective management of this pathology. The fundamental basis of the thrombophilia of PNH has not been elucidated. Currently, empiric anticoagulant therapy is the foundation for treating the thromboembolic complications of PNH. The role of warfarin prophylaxis, however, remains an area of active debate. Pregnancy in a patient with PNH presents special concerns about fetal/maternal well-being because of the high potential for thromboembolic complications. Bone marrow transplantation can be considered curative, but the decision to recommend this treatment must take into account factors related both to PNH and to comorbid conditions. Refining the technology for both gene therapy (by transducing stem cells with a functional PIG-A gene) and autotransplantation (by using stem cells selected for the expression of glycosyl phosphatidylinositol-anchored proteins) remain challenges for the future.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) arises in the setting of bone marrow injury. Thus, management decisions must take into account whether symptoms are a consequence of the underlying marrow failure or of the expansion of the clone of the PIG-A mutant hematopoietic cells. The primary clinical manifestations of PNH are intravascular hemolysis and thrombophilia. Currently available options for treatment of the hemolysis of PNH are unsatisfactory, but the recent development of specific inhibitors of complement for use in treating human disease should make possible effective management of this pathology. The fundamental basis of the thrombophilia of PNH has not been elucidated. Currently, empiric anticoagulant therapy is the foundation for treating the thromboembolic complications of PNH. The role of warfarin prophylaxis, however, remains an area of active debate. Pregnancy in a patient with PNH presents special concerns about fetal/maternal well-being because of the high potential for thromboembolic complications. Bone marrow transplantation can be considered curative, but the decision to recommend this treatment must take into account factors related both to PNH and to comorbid conditions. Refining the technology for both gene therapy (by transducing stem cells with a functional PIG-A gene) and autotransplantation (by using stem cells selected for the expression of glycosyl phosphatidylinositol-anchored proteins) remain challenges for the future.

KW - Complement

KW - Hemolysis

KW - PNH

KW - Therapy

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0037974782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037974782&partnerID=8YFLogxK

M3 - Article

C2 - 12627847

AN - SCOPUS:0037974782

VL - 77

SP - 125

EP - 132

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -